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Quantifying the Clinical Significance of Cannabis
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Abstract
Background and Aims: Questions over the clinical significance of cannabis withdrawal have hindered its inclusion as a
discrete cannabis induced psychiatric condition in the Diagnostic and Statistical Manual of Mental Disorders (DSM IV). This
study aims to quantify functional impairment to normal daily activities from cannabis withdrawal, and looks at the factors
predicting functional impairment. In addition the study tests the influence of functional impairment from cannabis
withdrawal on cannabis use during and after an abstinence attempt.
Methods and Results: A volunteer sample of 49 non-treatment seeking cannabis users who met DSM-IV criteria for
dependence provided daily withdrawal-related functional impairment scores during a one-week baseline phase and two
weeks of monitored abstinence from cannabis with a one month follow up. Functional impairment from withdrawal
symptoms was strongly associated with symptom severity (p = 0.0001). Participants with more severe cannabis dependence
before the abstinence attempt reported greater functional impairment from cannabis withdrawal (p = 0.03). Relapse to
cannabis use during the abstinence period was associated with greater functional impairment from a subset of withdrawal
symptoms in high dependence users. Higher levels of functional impairment during the abstinence attempt predicted
higher levels of cannabis use at one month follow up (p = 0.001).
Conclusions: Cannabis withdrawal is clinically significant because it is associated with functional impairment to normal daily
activities, as well as relapse to cannabis use. Sample size in the relapse group was small and the use of a non-treatment
seeking population requires findings to be replicated in clinical samples. Tailoring treatments to target withdrawal
symptoms contributing to functional impairment during a quit attempt may improve treatment outcomes.
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substance to alleviate withdrawal. Cannabis however, unlike other
drugs, does not currently include the seventh criterion of
withdrawal for diagnosing a cannabis use disorder in the DSMIV. This is due to debate about the clinical significance of the
cannabis withdrawal syndrome.
The evidence-base for cannabis withdrawal [2,3,4,5,6,7] has led
to a proposal to include it in the DSM-5 ><(see and [8,9]), which
could increase the prevalence of cannabis dependence diagnoses in
the community [10]. Increases in the prevalence of any mental
health disorder can have ramifications for treatment service
provision, highlighting the importance of ensuring that cannabis
withdrawal is clinically significant. To address this, a valid and
reliable Cannabis Withdrawal Scale (CWS) is in the early phases of
development, and the initial study validated the CWS via selfratings of the intensity of withdrawal symptoms during cannabis
abstinence [11]. While measurement of symptom intensity per se is

Introduction
The Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) requires that a mental health diagnosis ‘‘..causes
clinically significant distress or impairment in social, occupational,
or other important areas of functioning’’ ([1], p.358) in order to
reduce false positive diagnoses (i.e. incorrectly labelling somebody
with a mental health disorder). For DSM-IV drug dependence, at
least three of the following seven diagnostic markers must cause
clinically significant functional impairment ([1], p.181–183): 1.
tolerance to the substance, 2. consumption in larger amounts or for longer
periods than intended, 3. a persistent desire or unsuccessful attempts to cut
down, 4. a great deal of time spent obtaining, using or recovering from the
substance, 5. important activities are given up or reduced because of the
substance, 6. substance use is continued despite the knowledge that it causes
problems, 7. the presence of characteristic withdrawal symptoms or use of
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people who were prepared to abstain from cannabis for a twoweek period for research purposes. Inclusion criteria included: (a)
cannabis use on five or more days per week over the previous three
months; (b) current cannabis dependence; (c) previous experience
of at least one cannabis withdrawal symptom; and (d) willingness
to quit cannabis for two weeks. Exclusion criteria included: (a)
moderate or severe dependence on other substances except
caffeine and nicotine; (b) substance-related treatment in the last
three months; and (c) pregnancy or planning on becoming
pregnant during the study. After a complete description of the
study to the participants, written informed consent was obtained.

a central tenet of clinical scales of alcohol and other drug
withdrawal to date [12,13,14,15,16], intensity measures do not
necessarily capture the clinical significance associated with each
symptom or with the syndrome as a whole. In addition to
measuring the intensity of withdrawal symptoms, a more direct
method to assess their clinical significance would draw on the
DSM definition, and explicitly quantify how much symptoms
impair normal daily functioning such as required for work, family
life, and social functioning.
Research attempting to demonstrate the clinical significance of
cannabis withdrawal has used two approaches: (a) linking withdrawal
intensity to distress and/or substance use [5,6,17,18,19,20,21,22],
and (b) demonstrating that cannabis withdrawal is of a similar
magnitude and has similar consequences to nicotine withdrawal, a
well accepted clinically valid syndrome [20,23,24]. In regards to
linking withdrawal symptoms to cannabis use, two retrospective
studies showed that craving was the most highly endorsed
withdrawal symptom by people who relapsed, followed by
irritability, anger and boredom [4,5]. However the use of only
relapse as a measure of clinical significance may mask the extent to
which symptoms led to functional impairment, as those who
maintained abstinence may still have experienced clinically significant negative consequences from cannabis withdrawal (e.g.
relationship or work problems resulting from the withdrawal
syndrome).
Two studies have looked at the clinical significance of individual
cannabis withdrawal symptoms using Likert scales to tease apart
variation in the level of functional impairment. In a retrospective
survey of adults who made a recent quit attempt, Budney et al.
(2008) [20] used a 10-point Likert scale to show that the intensity of
aggression, anger, anxiety, cravings, and depression symptoms
contributed to cannabis relapse. Allsop and colleagues [11] used a
10-point Likert scale in a prospective study using a nonclinical
outpatient population to measure withdrawal symptom intensity as
well as the functional impairment caused by each symptom. The
items causing the most impairment to normal daily functioning
were: trouble getting to sleep, angry outbursts, imagining being
stoned (cravings), loss of appetite, feeling easily irritated, and
nightmares or strange dreams. The present study extends that
work by exploring whether the functional impairment reported
during abstinence is clinically significant, and what factors predict
it.
This study tested in a non clinical sample of non-treatment
seekers, (1) whether the level of functional impairment during
abstinence is predicted by severity of dependence, or pre-quit
attempt cannabis use levels, whilst controlling for age and gender,
and (2) what the relationship is between the intensity of cannabis
withdrawal symptoms and the level of associated functional
impairment. In addition the study had the following exploratory
aims: (a) to test the hypothesis that relapse to cannabis use is
associated with greater levels of functional impairment from
cannabis withdrawal symptoms, (b) to test the hypothesis that
greater functional impairment during the abstinence attempt is
predictive of a greater amount of cannabis consumed during a one
month follow-up period, and (c) to test what factors predict time to
relapse.

Measurements
A phone screening interview was used to collect demographics,
cannabis dependence severity using the Severity of Dependence
Scale (SDS) [25,26], and hazardous alcohol consumption using the
Alcohol Use Disorders Identification Test (AUDIT) [27]. The
SDS contains five items and uses a four-point response scale and is
reported to have high internal consistency (Chronbach’s alpha = 0.83, high test-retest reliability (Interclass Correlation
Coefficient (ICC) = 0.88), and good concurrent validity [26,28].
The AUDIT is a 10-item questionnaire developed by the World
Health Organisation, each item is scored on a four-point scale,
and different question groups measure hazardous consumption or
dependence behaviour. The AUDIT’s psychometric properties
have been demonstrated to be excellent in a wide range of studies,
with high internal consistency (Chronbach’s alpha ,0.83), testretest reliability (ICC = 0.87–0.93) and good concurrent validity
[29]. Telephone administration has proved efficient and successful
for both the AUDIT [30,31,32] and the SDS [33,34]. The
Structured Clinical Interview for DSM Disorders-Research
Version (SCID-RV) [35] was administered at the baseline
laboratory visit by a trained psychologist to assess for Axis-I
psychiatric disorders. The Timeline Followback (TLFB) [36,37]
was used to assess alcohol, tobacco and cannabis use at each
laboratory visit. The major urinary metabolite of cannabis, 11nor-D9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH)
was quantified by gas chromatography-mass spectrometry and
normalized by urinary creatinine level (THC-COOH/creatinine)
to validate self reported abstinence [38].
An online version of the CWS [11], including a functional
impairment subscale, was used to quantify the impact of cannabis
withdrawal symptoms on normal daily functioning using a 10point Likert scale question asking how each symptom NEGATIVELY impacted getting through or completing normal daily
activities, assessed alongside withdrawal intensity (see Table 1).
The CWS has been shown to have excellent psychometric
properties, with high internal reliability (Chronbach’s alpha = 0.91) and test-retest reliability (ICC = 0.95) [11]. Whilst
the withdrawal symptoms on the CWS do not represent functional
impairment per se (e.g. not being able to socialise), the negative
impact component on the CWS anchored to each symptom
specifically addresses this question by having patients give an
indication of the magnitude of impairment to normal daily
functioning caused by each symptom.

Study procedures and cannabis use
The University of New South Wales Human Research Ethics
Committee approved all procedures (Approval number: HREC
09152). Study participants filled out the CWS online daily during a
one-week baseline ‘‘smoking as usual’’ period, and a two-week
cannabis abstinence attempt. The cannabis abstinence attempt
was supported with a one-hour psychological intervention and
contingency management payments totalling AU$450 for adher-

Methods
Participants
Current cannabis users who were not seeking treatment for their
cannabis use were recruited from Sydney, Australia using a
targeted postcard campaign (http://www.webcitation.org/
69yO6gGfy) and advertisements in local newspapers asking for
PLOS ONE | www.plosone.org
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Table 1. The cannabis withdrawal scale.

Not at all

Moderately

1

The only thing I could think
about was smoking some
cannabis

2

I had a headache

3

I had no appetite

4

0

Negative Impact on
daily activity (0–10)

Extremely

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

0

1

2

3

4

5

6

7

8

9

10

I felt nauseous (like vomiting) 0

1

2

3

4

5

6

7

8

9

10

5

I felt nervous

0

1

2

3

4

5

6

7

8

9

10

6

I had some angry outbursts

0

1

2

3

4

5

6

7

8

9

10

7

I had mood swings

0

1

2

3

4

5

6

7

8

9

10

8

I felt depressed

0

1

2

3

4

5

6

7

8

9

10

9

I was easily irritated

0

1

2

3

4

5

6

7

8

9

10

10

I had been imagining being
stoned

0

1

2

3

4

5

6

7

8

9

10

11

I felt restless

0

1

2

3

4

5

6

7

8

9

10

12

I woke up early

0

1

2

3

4

5

6

7

8

9

10

13

I had a stomach ache

0

1

2

3

4

5

6

7

8

9

10

14

I had nightmares and/or
strange dreams

0

1

2

3

4

5

6

7

8

9

10

15

Life seemed like an uphill
struggle

0

1

2

3

4

5

6

7

8

9

10

16

I woke up sweating at night

0

1

2

3

4

5

6

7

8

9

10

17

I had trouble getting to sleep at0
night

1

2

3

4

5

6

7

8

9

10

18

I felt physically tense

0

1

2

3

4

5

6

7

8

9

10

19

I had hot flashes

0

1

2

3

4

5

6

7

8

9

10

Instructions: This version of the CWS asks about symptoms experienced over the last 24 hours, and can be administered by an interviewer OR by self report.
The following statements describe how you have felt over the last 24 hours. Please circle the number that most closely represents your personal experiences for each
statement. For each statement, please rate its negative impact on normal daily activities on the same scale (0 = Not at all to 10 = Extremely), writing the number in the
right hand column.
Score by summing each items value to a maximum withdrawal score of 190 (you can derive two scores from the scale: one for withdrawal intensity and one for the
negative impact of withdrawal – each separate score has a theoretical maximum of 190).
Reprinted from Drug and Alcohol Dependence, Vol 119, Allsop, D.J., Norberg, M.M., Copeland, J., Fu, S., Budney, A.J. The Cannabis Withdrawal Scale development:
Patterns and predictors of cannabis withdrawal and distress, 123–129., Copyright (2011), with permission from Elsevier (License number 2872801116106).
doi:10.1371/journal.pone.0044864.t001

ence to study protocol, including the provision of urine samples
indicating no cannabis use during the two week abstinence period.
Participants in the study visited the research facility five times over
the course of their involvement in the study: once at baseline, once
after a week of smoking as usual, once after the first week of
abstinence, and again at the end of the second week of abstinence.
A final visit for follow-up interviews was performed one month
after the end of the experimental abstinence period. Study
procedures, including eligibility screening, and a full documentation of face to face interview schedules, the content of the 1 hour
psychological intervention at the beginning of the quit attempt and
monitoring of study adherence (including confirmation of cannabis
abstinence) are described in a previous report [11]. If participants
used cannabis in the first abstinence week, they were offered an
opportunity to restart the abstinence period. If they restarted, data
from their first abstinence attempt, up to the day of cannabis use,
is used in the current functional impairment analysis. If
participants used cannabis during the second week of abstinence,
any post cannabis use withdrawal data were discarded and all
functional impairment data collected prior to cannabis use was
retained for analysis. Participants were considered to have used
cannabis if they self-reported cannabis use or if their THCPLOS ONE | www.plosone.org

COOH:creatinine ratios showed any increase during the abstinence phase relative to their one week ‘smoking as usual’ baseline
phase levels [39]. Data from two participants were removed from
all analyses due to a conflict between their self-reported cannabis
use and urinalysis tests at weeks 1 and 2 of the abstinence period.
All other participants’ cannabis abstinence reports were validated
by urinalysis. Participant’s cannabis use during the month
following the end of their abstinence period was monitored by
self report (TLFB) and confirmed with a single urinalysis at the one
month follow up interview requiring THC-COOH:creatinine
levels to be below 50 ng/ml to be classed as abstinent.

Analysis
Descriptive statistics were reported as frequency and means with
standard deviations and ranges (except where non-parametric
analyses were performed, where continuous variables were
described using medians and interquartile range). Analysis of
Variance, Pearson Chi Square and Fishers exact test were used to
compare clinical characteristics of: (1) participants who relapsed to
those who didn’t relapse, and (2) participants who were lost to
follow up to those who were not lost to follow-up.
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Aim 1: Identify if the level of functional impairment
during abstinence is predicted by severity of
dependence, or pre-quit attempt cannabis use levels,
whilst controlling for age and gender

Aim 2: Identify if a relationship exists between
withdrawal related functional impairment and the
severity of cannabis withdrawal symptoms
In order to examine the relationship between withdrawal
severity and functional impairment, it was determined that all
other possible drivers of functional impairment should first be
controlled for. Hence the full model from Aim 1, examining the
predictors of functional impairment was retained, with the
addition of a final step. In this final step, the effect of adding
CWS symptom severity scores on the explained observed variance
in functional impairment was examined.

To explore whether the level of functional impairment could be
predicted by cannabis use, severity of dependence, age or gender,
a General Linear Mixed Model (GLMM) was constructed with
total daily functional impairment scores (summed across all 19
valid items in a day) as the dependent variable. The dependent
variable represents repeated measurements, and the GLMM
allows explicit modelling of covariance between daily measures
within individual subjects (using an autoregressive covariance
structure of order 1). The model was constructed in a hierarchical
manner, with the null model consisting of the intercept only. Step
one explored the effect of time in abstinence on functional
impairment scores, as abstinence represents the primary and most
fundamental independent variable generating withdrawal phenomena. Step two added the non-cannabis use related covariates
(age and gender) in order to ensure they are controlled for ahead
of adding the cannabis use variables, which are the hypothesised
drivers of withdrawal related functional impairment. Step three
added cannabis-related variables (pre-quit cannabis use levels and
scores on the SDS), to test their relative explanatory power having
controlled for other variables. SDS scores were analysed as
continuous variables as dichotomising loses valuable statistical
information and power and obscures any nonlinearities between
variables [40,41]. However for graphical purposes the data were
split into high and low SDS groups.
As mixed-effects models do not generate traditional R2 values,
the variance in withdrawal related functional impairment
explained by the variables at each step of the model was estimated
using a pseudo R2 calculated from the log likelihood ratios output
from mixed models (termed R2LR) [42]. Because R2 values are
known to increase with the number of variables in a model,
irrespective of their predictive power, the model also presents
Akaikes Information Criteria [43] as a measure of model fit for
each step, as this value penalises models for increased complexity.
Because of sample size restrictions the analysis was not powered to
look at the interactions in this longitudinal analysis.

Exploratory Aim 1: Relapse to cannabis use is associated
with greater levels of functional impairment from
cannabis withdrawal symptoms
To assess if participants who relapsed during the abstinence
period had higher levels of impairment from cannabis withdrawal,
each symptom’s functional impairment score was analysed
separately using a univariate approach. Rank transformed
functional impairment scores were used as dependent variables
in a series of non parametric two way repeated measures Analysis
of Variance [44], with time as the repeated measure (baseline week
vs. abstinence) and relapse group as the between subject factor.
Symptoms were then sorted (separately for each SDS group [45])
on their univariate F-values for the interaction between time and
relapse group.
Withdrawal symptoms significant in the univariate analyses
were then entered as independent variables in a multivariate
logistic regression [44] by subtracting impairment scores from
abstinence week 1 from baseline smoking as usual scores to create
‘change’ variables. Membership of the relapse group (or not) was
the binary dependent variable. To fully explore the withdrawal
parameter space contributing to relapse, the selected withdrawal
symptoms were grouped into either somatic or negative affect
symptoms.

Exploratory Aim 2: Greater functional impairment during
the abstinence attempt is predictive of a greater amount
of cannabis consumed during a one-month follow-up
period
To test the impact of functional impairment during abstinence
on levels of cannabis use at one-month follow up, a linear

Table 2. Demographics and substance use.

Variable

Dependent users (N = 49)

Gender (% Male)

67

Age (years)

30 (Range: 18–57; SD 9.59)

Age of first cannabis use (years)

16.1 (Range: 11–28; SD 3.16)

Age of transition to regular cannabis use (years)

19.6 (Range: 14–40; SD 4.97)

Cannabis Severity of Dependence Scale Score

7.7 (Range: 3–15; SD 3.03)

# SCID cannabis dependence criteria endorsed

5.62 (Range: 3–7; SD 1.05)

Amount of cannabis consumed in baseline ‘smoking as usual’ week (in grams)

7.76 (Range: 1.04–43.86; SD 9.29)

# days abstinent from cannabis in the previous 3 months

0.45 (Range: 0–5; SD 0.94)

Amount of cannabis consumed per week during the one month follow up period (in grams)

2.81 grams (Range: 0–17, SD 3.1)

# Cigarettes consumed per week in the baseline ‘smoking as usual’ week

40.3 (Range: 0–150, SD 47.7)

# Cigarettes consumed per week during the two weeks of cannabis abstinence

54.02 (Range: 0–192, SD 57.4)

doi:10.1371/journal.pone.0044864.t002

PLOS ONE | www.plosone.org

4

September 2012 | Volume 7 | Issue 9 | e44864

The Clinical Significance of Cannabis Withdrawal

Figure 1. Flow chart depicting study participation.
doi:10.1371/journal.pone.0044864.g001

diagnoses [11]), all were considered mild dependencies that would
not interfere with study participation. The comparison of
functional impairment between those who did and did not use
cannabis during the abstinence period was carried out on the
remaining 46 participants who provided full or partial abstinence
data. Ten people used cannabis during the attempted abstinence
phase after an average of five days in abstinence (x 5.1, SD 3.1,
range: 1–10; Figure 1), which coincided with peak functional
impairment (Figure 2).

regression (Generalized Linear Model – GLM) was constructed
with average weekly cannabis use at follow-up as the dependent
variable. The independent predictor was the CWS sum total
functional impairment score, calculated by averaging daily scores
across the two-week abstinence period. Pre-study cannabis use
levels and SDS scores were controlled for as covariates. CWS
functional impairment data was normalized with a square root
transformation (as the data had a long positive tail).

Exploratory Aim 3: What factors predict time to relapse?
Predicting withdrawal related functional impairment

A Generalised Linear Model was used to analyse the time taken
to relapse (in days) (dependent variable), with the average change
in functional impairment scores between baseline and abstinence
as the independent variable. The analysis controlled for age,
gender, SDS scores and the mean weekly cannabis use prior to
entering the study.
All analyses were carried out using SPSS version 20.

The results of the model to identify factors predicting levels of
functional impairment from cannabis withdrawal are listed in
Table 3. The null model consists of only the intercept, and
demonstrates significant heterogeneity in functional impairment
scores between study participants. The addition of time in
abstinence at step 1 was a significant predictor of functional
impairment, explaining 8.9% of the variance. Neither of the
demographic variables were significant in step 2, increasing
explained variance by only 0.0008%. The addition of cannabis
related variables in step 3 increased explained variance to 14%,
and inspection of the univariate statistics in the full model show
that only the severity of dependence (SDS scores) contributed to
this increased predictive power in the model (Table 3; Figure 2).

Results
Of the 131 people phone screened forty-nine enrolled in the
study (see Table 2 for demographics and substance use information), one dropped out during baseline, and two dropped out at the
start of abstinence week 1 without providing any abstinence data
(Figure 1). Whilst a small proportion of study participants were
diagnosed with current or past alcohol or other substance use
disorders; see prior report for a full exposition of other psychiatric

PLOS ONE | www.plosone.org
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Figure 2. Variability of functional impairment from cannabis withdrawal over time in two subgroups formed by a ‘‘clinically
informed’’ split in Severity of Dependence Scale scores. Total daily functional impairment scores for high and low SDS groups (horizontal lines
are the average functional impairment scores rated during the baseline ‘‘smoking as usual’’ week for each SDS group). For the purposes of graphical
demonstration, SDS group was assigned based on a clinically informed split at 8 or above for high dependent users [45].
doi:10.1371/journal.pone.0044864.g002

multivariate model, only increased physical tension is a significant
predictor of relapse. Neither the negative affect model nor the
combined negative affect and somatic symptoms model had
significant omnibus tests for predictors of relapse, although within
the combined model, physical tension remained the only
significant predictor of relapse, with every one point increase
above baseline physical tension levels leading to a four times
increase in the proportional odds of relapsing.
As sample sizes are small in the relapse groups, a post hoc analysis
based on the pre-post changes in Total CWS Functional
Impairment Scores between relapsers and non relapsers from
both SDS groups combined (No relapse: Baseline mean (SD) 19.07
(24.5), Abstinence week 1 mean (SD) 26.19 (29.72); Relapse:
Baseline mean (SD) 16.45 (11.53), Abstinence week 1 mean (SD)
33.47 (35.36)) suggests that an effect size (Cohens f) of 0.18 was
observed. When used in a between factors mixed ANOVA power
analysis (with 2 groups and 2 measurements), with a = 0.05 and a
minimum power of 80%, this effect size suggests that a total
sample size of 64 (32 in each group) would be required to detect an
effect of this magnitude between people who relapse and those
who do not.
The time to relapse variable was normally distributed amongst
those who relapsed (Shapiro-Wilk (9) = 0.96, p = 0.8) but was not
so when the full sample was considered (i.e. including people who
succeeded in remaining abstinent for the full 14 days; ShapiroWilk (45) = 0.52, p = 0.0001). There was no difference in any of the
following variables between those who relapsed and those who
didn’t: age (F1,45 = 1.69, p = 0.2, gender (Fishers exact test,
p = 0.69), endorsement of SCID withdrawal dependence criteria
(Fishers exact test, p = 0.7), the number of SCID dependence
criteria endorsed (Pearson Chi Square = 0.83, p = 0.9), SDS score
(F1,45 = 0.005, p = 0.94), or the amount of cannabis they smoked

Relationship between withdrawal severity and associated
impairment
Adding withdrawal severity scores at step 4 of the ‘‘predictors of
functional impairment’’ model (Table 3) causes a large jump in
explained variance to 51%, demonstrating a strong relationship
between withdrawal severity and the functional impairment
caused by withdrawal (Table 3).

Withdrawal related functional impairment and relapse
Univariate statistics comparing the effects of functional impairment from each withdrawal symptom on chances of relapse are
shown in Table 4 (high SDS) and Table 5 (low SDS). Withdrawal
symptoms causing increased levels of functional impairment for
people who relapsed are towards the top of the tables. Despite
both high and low SDS groups having an equal number of people
who relapsed (n = 5 in each group), only the high SDS group had
significantly elevated functional impairment from cannabis withdrawal in those who relapsed (Tables 4 and 5). In the high SDS
group, a significant interaction effect between time (baseline vs.
abstinence) and relapse group was observed in seven cannabis
withdrawal symptoms (I had trouble getting to sleep (F1,23 = 8.38,
p = 0.008), I had no appetite (F1,23 = 7.95, p = 0.01), I felt anxious
(F1,23 = 7.93, p = 0.01), Life felt like an uphill struggle (F1,23 = 7.04,
p = 0.01), I felt physically tense (F1,23 = 5.29, p = 0.03), I had mood
swings (F1,23 = 4.84, p = 0.04) and I felt depressed (F1,23 = 4.49,
p = 0.05); see Table 4).
The multivariate analysis used a logistic regression to test
whether the withdrawal symptoms identified (above) as causing
significant functional impairment in high SDS relapsers were
predictive of relapse for the group as a whole. The omnibus tests in
Table 6 show that increased somatic withdrawal symptoms are
predictive of relapse, and that within the somatic symptoms
PLOS ONE | www.plosone.org
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Table 3. Summary of hierarchical repeated measures mixed model analysis of factors predicting functional impairment from
cannabis withdrawal.

Variable

F-value(Degrees

of Freedom)

p-value

AICa

DR2LR

R2LRb

Total daily functional impairment score
Null model
Intercept

6767.04
32.45

(1,41.99)

Step 1
Time in abstinence

2.35(14,365.01)

0.004

Age

0.69(1/40.01)

0.41

Gender

0.19(1,40.11)

0.66

Cannabis Use (g/week)

0.81(1/33.98)

0.38

SDS Score

4.95(1/34.39)

0.03

671.16(1/776.907)

0.0001

Step 2

Step 3

Step 4
Total severity of cannabis withdrawal

0

0.0001
6686.83

0.089

0.089

6679.71

0.0008

0.097

6638.25

0.04

0.14

6164.36

0.37

0.51

a

. Akaikes Information Criterion,
. Likelihood ratio based R2 approximation.
doi:10.1371/journal.pone.0044864.t003
b

prior to entering the study (F1,45 = 0.031, p = 0.86). Functional
impairment scores did not predict the number of days taken to
relapse when controlling for age, gender, SDS score and pre-study
cannabis use (F5, 41 = 0.56, p = 0.7).

(Table 3 and Figure 2). The strongest predictor of functional
impairment to normal daily activities from cannabis withdrawal
was the severity of the cannabis withdrawal symptoms (Table 3).
As tobacco use increased during abstinence compared to the
baseline ‘smoking as usual’ week (Table 2), it is unlikely that the
observed impairment was due to nicotine withdrawal. Relapse to
cannabis use was associated with higher levels of functional
impairment in the high SDS user group (Table 4). Despite the fact
that members of the low SDS group also relapsed during the
abstinence attempt, their relapse was not associated with
significant levels of functional impairment from withdrawal
(Table 5).
Whilst the univariate analysis showed a subset of withdrawal
symptoms were associated with increased functional impairment
in those who relapsed (I had trouble getting to sleep, I had no
appetite, I felt anxious, Life felt like an uphill struggle, I felt
physically tense, I had mood swings and I felt depressed; Table 4),
the multivariate predictive model indicated that only ‘‘physical
tension’’ remained a significant predictor of relapse for the whole
group (Table 6). These findings may suggest that somatic and
negative affect symptoms respond similarly during a quit attempt,
but somatic withdrawal symptoms may be more pertinent to
predicting relapse in this sample of non-treatment seekers. If the
same were observed in a clinical sample, this may be useful for
counselling cannabis smokers on what changes to expect during
their quit attempt. However it is important to stress that the
multivariate models may suggest which withdrawal symptoms
integrate relapse risk information efficiently, rather than revealing
specific causal paths.
It is of note that the average level of functional impairment
caused by cannabis withdrawal symptoms was relatively mild (the
highest median total CWS functional impairment scores during
abstinence were 60 out of a possible 190 during week 1 of
abstinence in high SDS users who relapsed; Table 4) among this
sample of non-treatment seeking users. Several factors should be
considered when interpreting these data. First, the data represent
only one aspect of the withdrawal syndrome – that being cannabis
users’ perception of the impact of withdrawal symptoms on
carrying out their normal daily activities. Functional impairment

The effects of functional impairment during abstinence
on cannabis use at follow up
To assess the relationship between functional impairment
during abstinence and cannabis use during the one-month
follow-up data were available for 40 of the 46 study participants.
The six participants lost to follow up experienced significantly
greater functional impairment from their withdrawal symptoms
during the first week of abstinence (relative to baseline) than those
who were followed up (week 1 mean total functional impairment
increase for those lost to follow up = 26.8, mean increase for those
who were able to be followed up = 6.8; F1, 45 = 6.6, p = 0.01),
however the two groups of participants did not differ in their
functional impairment scores during week 2 of abstinence
(F1, 45 = 0.001, p = 0.97). Those lost to follow up were more likely
to have relapsed: 40% (n = 4) of those who relapsed (n = 10) could
not be followed up compared to only 5% (n = 2) of those who were
able to maintain abstinence for the full two week period (n = 36)
(Fishers exact test, p = 0.014). Those lost to follow up did not differ
from the remaining 40 study participants in any of the following
variables: age (F1,45 = 0.39, p = 0.53), gender (Fishers exact test,
p = 0.65), SDS Score (F1, 45 = 0.48, p = 0.49), or the amount of
cannabis they consumed prior to entering the study (F1,45 = 0.06,
p = 0.8). Higher levels of functional impairment during the
abstinence period significantly predicted higher levels of selfreported cannabis use at 1 month follow up (b = 0.019 (SE 0.39),
t = 4.197, p = 0.0001), after controlling for baseline cannabis use
levels (b = 0.025 (SE 0.01), t = 2.185, p = 0.029) and SDS scores
(b = 20.19 (SE 0.06), t = 23.3, p = 0.001).

Discussion
Consistent with previous work on withdrawal severity [11],
higher levels of dependence on cannabis were associated with
higher levels of functional impairment from cannabis withdrawal
PLOS ONE | www.plosone.org
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1 (2)
1 (2)
0.5 (1)
0 (0)
16 (31.5)
0 (1)
1 (2.75)
0.5 (2)
2 (3.75)
1 (2)
1 (3.75)
0 (2.75)
0 (0)
2 (2.75)
0 (2)

I felt physically tense

I had mood swings

I felt depressed

I felt nauseous (like vomiting)

Total CWS functional impairment score

I yawned a lot

I was easily irritated

I felt nervous

I woke up early

I felt worried

Thinking about smoking

I had some angry outbursts

I had a stomach ache

I felt tired

Imagining being stoned

1 (2.75)

I woke up sweating at night

I felt restless

2 (3)

1 (3.5)

1 (1.75)

0 (1)

0 (2.5)

2 (4)

2 (2.75)

0 (0.75)

1 (2.75)

2.5 (4.5)

2 (3)

1 (4)

1 (3.75)

1.5 (4)

0 (2)

24 (46.75)

0 (1)

1 (3)

1 (4)

2 (3)

2 (3.75)

2 (5)

1 (3)

1.5 (4)

Abstinence Week
1 Median (IQR)

3.5 (2.5)

0.5 (4.75)

0.5 (1.75)

0 (0.12)

0 (0.75)

2.5 (4.75)

3 (2.25)

0 (0.75)

1 (0.75)

3.5 (4.5)

0 (3)

1 (3.5)

0 (3)

1.5 (3.25)

1 (2.25)

24.5 (13.75)

0.83 (0.36)

0 (3.75)

1 (0.34)

1.5 (2.5)

0 (3.75)

0 (3)

1 (3.5)

0 (4.5)

Baseline
Median (IQR)

Relapse (n = 5)

5 (6)

3 (6.25)

0.5 (4)

0.2 (2.35)

0 (1.5)

6 (7.25)

3 (3.5)

0 (2.25)

3.5 (4.75)

6.5 (5.5)

1.5 (7.5)

2 (1.5)

1 (6)

5 (5.2)

1.5 (4.75)

60 (62)

0.57 (4.7)

3 (6)

3.5 (4.75)

4.5 (5.5)

3 (6)

2.5 (6.75)

5 (0.75)

5 (5.5)

Abstinence Week
1 Median (IQR)

0.007

0.009

0.007

0.03

1.35

0.13

0.13

0.14

0.16

0.61

0.65

0.68

0.8

0.83

0.87

0.91

1.33

1.99

2.15

2.35

3.13

3.52

3.53

3.72

F(1,23)

0.94

0.93

0.94

0.86

0.74

0.73

0.73

0.72

0.69

0.44

0.43

0.42

0.38

0.37

0.36

0.35

0.26

0.17

0.16

0.14

0.09

0.07

0.07

0.07

P

Time (within subjects)

3.61

1.45

0.05

0.9

0.04

3.08

1.9

0.008

2.16

4.06

0.13

0.03

0.002

2.76

2.62

2.04

0.003

0.1

0.59

1.21

0.05

0.03

2.5

0.43

F(1,23)

0.07

0.23

0.83

0.35

0.85

0.09

0.19

0.93

0.16

0.06

0.72

0.86

0.97

0.11

0.12

0.17

0.96

0.75

0.45

0.28

0.83

0.87

0.13

0.51

P

Relapse vs no relapse
(between subjects)

0.02

0.02

0.02

0.08

0.26

0.29

0.29

0.3

0.36

1.37

1.45

1.53

1.81

1.88

1.96

2.04

2.98

4.49

4.84

5.29

7.04

7.93

7.95

8.38

F(1,23)

0.9

0.88

0.91

0.79

0.62

0.59

0.59

0.59

0.55

0.25

0.24

0.23

0.19

0.19

0.18

0.17

0.09

0.05

0.04

0.03

0.01

0.01

0.01

0.008

P

Time6relapse
(interaction)

Medians and Interquartile range (IQR) with results from a non parametric two way repeated measures ANOVA (using ranked data) comparing change in functional impairment between baseline and abstinence week 1, between
people who relapsed to cannabis use during the two weeks of attempted abstinence and those who didn’t. rANOVA results are presented for the main effect of relapse group, the main effect of time, and the interaction of time
and relapse group. The table is sorted by the F-value from the rANOVA interaction result to reflect the relative order of withdrawal symptoms with respect to their association with relapse (e.g. items at the top of the table are those
that are most associated with relapse when comparing functional impairment changes from baseline to week one of abstinence).
doi:10.1371/journal.pone.0044864.t004

0.5 (2)
0 (0.75)

I had a headache

0 (0)

1 (2.75)

Life felt like an uphill struggle

0 (0.75)

1 (3.75)

I felt anxious

I had nightmares or strange dreams

0 (3.25)

I had hot flashes

1 (2)

I had no appetite

BaselineMedian (IQR)

No relapse (n = 20)

I had trouble getting sleep

Withdrawal Symptom

Table 4. Which withdrawal symptoms are associated with relapse in High Severity of Dependence Scale score users?
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0 (1.75)
0 (1)

Life felt like an uphill struggle

I felt worried

0.5 (1)

0 (2)

0 (1)

0 (0)

I felt physically tense

I felt nauseous (like vomiting)

0 (0.75)

0 (1)

0 (0)

0 (1)

2 (3)

0 (0.5)

0 (1)

0 (0.5)

0 (0.21)

0 (2)

0 (1)

0 (0.5)

13 (15)

0 (0.5)

0 (0.5)

0 (0)

0 (1.5)

0 (1)

1 (1.5)

0 (3)

1 (1.5)

0 (1)

0 (2)

1 (3)

0 (0)

0 (1)

Baseline
Median (IQR)

Relapse (n = 5)

0 (0.36)

0 (1.5)

1 (2)

0 (0.5)

0 (2)

0 (0.5)

0 (0.08)

0 (1)

0 (1)

0 (0.5)

8 (18)

0 (1)

0 (1.5)

0 (0.5)

0 (2.5)

0 (1.5)

0 (2.5)

0 (2)

0 (2)

0 (2.5)

0 (0.5)

0 (2)

0 (0)

0 (0.5)

Abstinence Week
1 Median (IQR)

0.01

0.01

0.02

0.02

0.02

0.03

0.06

0.07

0.08

0.1

0.1

0.1

0.11

0.12

1.29

0.15

0.2

0.22

0.24

0.28

0.3

0.43

0

0.57

F(1,19)

0.94

0.94

0.9

0.9

0.89

0.87

0.81

0.8

0.78

0.76

0.75

0.75

0.74

0.73

0.72

0.7

0.66

0.65

0.63

0.6

0.59

0.52

1

0.46

P

Time (within subjects)

0.46

0

1.26

0.03

0.2

0.82

3.92

0

0.01

2.08

0.2

0.01

0.33

2.64

0.27

0.01

0.15

0.22

0.06

0.21

0.28

0.07

0

0.59

F(1,19)

0.51

0.98

0.28

0.87

0.66

0.38

0.06

0.95

0.91

0.17

0.66

0.91

0.58

0.12

0.61

0.94

0.7

0.65

0.81

0.65

0.61

0.79

1

0.45

P

Relapse vs no relapse
(between subjects)

0.02

0.02

0.05

0.06

0.07

0.1

0.23

0.24

0.29

0.35

0.37

0.38

0.41

0.45

0.47

0.54

0.73

0.79

0.87

1.04

1.08

1.56

1.65

2.08

F(1,19)

0.88

0.89

0.82

0.8

0.79

0.75

0.64

0.63

0.6

0.56

0.55

0.55

0.53

0.51

0.5

0.47

0.41

0.39

0.36

0.32

0.31

0.23

0.22

0.17

P

Time6relapse
(interaction)

Medians and Interquartile range (IQR) with results from a non parametric two way repeated measures ANOVA (using ranked data) comparing change in functional impairment between baseline and abstinence week 1, between
people who relapsed to cannabis use during the two weeks of attempted abstinence and those who didn’t. rANOVA results are presented for the main effect of relapse group, the main effect of time, and the interaction of time
and relapse group. The table is sorted by the F-value from the rANOVA interaction result to reflect the relative order of withdrawal symptoms with respect to their association with relapse (e.g. items at the top of the table are those
that are most associated with relapse when comparing functional impairment changes from baseline to week one of abstinence).
doi:10.1371/journal.pone.0044864.t005

2 (2.75)
0 (1)

I felt tired

1.5 (3)

0 (1)

I felt depressed

0 (0.75)

0 (0)

0 (1)

I had no appetite

0 (0)

1 (1)

12.5 (16)

0 (1)

0 (0)

0 (1)

1 (2)

0 (1)

1 (1.7)

1 (2)

1 (2)

0 (1)

0 (1)

0.5 (1)

0 (0)

0.5 (2)

Abstinence Week
1 Median (IQR)

I had nightmares or strange dreams 0 0.75)

0 (2.75)
0 (1.75)

6 (11)

Total CWS functional
impairment score

I yawned a lot

0 (0.75)

I felt nervous

I had a headache

0 (1)
0 (0)

1 (2)

Thinking about smoking

I woke up sweating at night

0 (2)

I felt anxious

I had a stomach ache

0 (1)

I had some angry outbursts

0.5 (2)

Imagining being stoned
0 (1)

0 (1.75)

I woke up early

0.5 (1)

0 (2)

I felt restless

I had trouble getting sleep

0 (0)

I had hot flashes

I was easily irritated

0 (1)

BaselineMedian (IQR)

No relapse (n = 16)

I had mood swings

Withdrawal Symptom

Table 5. Which withdrawal symptoms are associated with relapse in Low Severity of Dependence Scale score users?
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Table 6. Best fitting multivariate models using somatic variables only, negative affect variables only, and then the combination
somatic and negative affect variables to predict relapse during the attempted abstinence.

Withdrawal measure

Wald/Omnibus Chi Sq

p value

Somatic variables only model

8.525

0.036

I had trouble getting to sleep (abstinence – baseline)

1.71

I had no appetite (abstinence – baseline)

0.93

I felt physically tense (abstinence – baseline)
Negative affect variables only model

OR

OR 95% CI

0.19

0.59

0.27, 1.29

0.33

1.38

0.71, 2.69

4.4

0.036

2.52

1.06, 5.99

3.03

0.55

I felt anxious (abstinence – baseline)

0.76

0.38

1.36

0.68, 2.75

Life felt like an uphill struggle (abstinence – baseline)

0.03

0.87

1.08

0.42, 2.82

I had mood swings (abstinence – baseline)

0.24

0.62

0.8

0.33, 1.93

I felt depressed (abstinence – baseline)

0.35

0.55

1.38

0.47, 4.11

10.82

0.15

1.98

0.16

0.58

0.27, 1.24

Combined somatic and negative affect model
I had trouble getting to sleep (abstinence – baseline)
I had no appetite (abstinence – baseline)

0.96

0.33

1.44

0.69, 3

I felt physically tense (abstinence – baseline)

4.77

0.02

3.74

1.14, 12.19

I felt anxious (abstinence – baseline)

0.05

0.83

1.1

0.46, 2.6

Life felt like an uphill struggle (abstinence – baseline)

0.59

0.44

1.6

0.47, 5.7

I had mood swings (abstinence – baseline)

1.7

0.19

0.47

0.15, 1.5

I felt depressed (abstinence – baseline)

0.087

0.77

0.81

0.21, 3.2

doi:10.1371/journal.pone.0044864.t006

delivery context. Performing the same study in a clinical treatment
seeking group may be expected to find more severe withdrawal
having greater negative consequences to daily life, with the
potential for greater levels of relapse. Examining withdrawal in
such clinical samples will be a fruitful area of future research. It is
also worthy of note that Table 4 shows measureable levels of
functional impairment at baseline (before abstinence from
cannabis) for the high SDS group. This is consistent with previous
studies of both cannabis [48] and tobacco [46] withdrawal, and is
expected as each individual will have their own baseline level of
functioning, for example a mild usual sleep problem or a usual
mildly depressed mood, which may become more substantial
during abstinence. Finally there was no external corroboration of
the self-reported functional impairment, or use of an alternative
functional impairment measure.
In conclusion, cannabis withdrawal is clinically significant
because it is associated with elevated functional impairment to
normal daily activities, and the more severe the withdrawal is, the
more severe the functional impairment is. Elevated functional
impairment from a cluster of cannabis withdrawal symptoms is
associated with relapse in more severely dependent users. Those
participants with higher levels of functional impairment from
cannabis withdrawal also consumed more cannabis in the month
following the end of the experimental abstinence period. Higher
levels of cannabis dependence (scores on the SDS) predicted
greater functional impairment from cannabis withdrawal. These
findings suggest that higher SDS scores can be used to predict
problematic withdrawal requiring more intense treatment that can
be monitored closely using the Cannabis Withdrawal Scale
(Table 1) [11]. Finally and speculatively, the finding that lower
levels of cannabis dependence predict lower levels of functional
impairment from withdrawal (and thus lower levels of relapse) may
indicate that stepped reductions in cannabis use prior to a quit
attempt could reduce dependence, and thus reduce levels of
withdrawal related functional impairment, improving chances of

received a uniformly lower endorsement for all of the symptoms
surveyed relative to symptom intensity scores [11]. Second, the
focus on average values across all of the participants in the study
masks the variation in functional impairment experienced between
people. As can be seen from the ‘interquartile range’ data
presented in Tables 4 and 5, some study participants reported that
cannabis withdrawal symptoms caused very high levels of
functional impairment. Third, the study population consisted of
non-treatment seekers, so it is reasonable to expect that higher
levels of withdrawal-related functional impairment would be
reported by treatment seekers, and this will be a fruitful avenue
for future research. Finally, whilst the cannabis withdrawal
syndrome is mild for most users, it appears comparable with
tobacco withdrawal [20,24,46] which is of well established clinical
significance.
This study has several notable limitations. The sample size is
small, which can lead to inflated Type I errors in the analyses, and
precludes conduct of factor analyses on the CWS to test any a priori
predictions on the underlying structure of the cannabis withdrawal
syndrome. The ad hoc analyses grouping selected symptoms into
somatic and negative affect variables used in this present work
would benefit from more rigorous factor analytical methods with
larger sample sizes. The relapse analysis was by necessity
opportunistic (hence we did not set out a formal a priori power
calculation for this analysis), and the small numbers of participants
in the relapse group suggest that any findings relating to relapse
would benefit from further research. The post-hoc power analysis of
total withdrawal scores suggests that ,64 participants (32 in each
group), would be required to detect a difference of the magnitude
observed in this study. However effect size calculation from small
sample sizes is prone to error [47], further supporting the need to
follow up the relapse findings with larger datasets. As mentioned
previously, a clear limitation of the present findings is that the
study population was generally non-treatment seeking, so it may
represent a conservative account of the findings in a treatment
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comments on the development of the study. Tim Slade, Barbara Toson,
Mathew Crowther and Jennifer Chalmers provided statistical advice and
discussion. David Burke helped prepare the images.

achieving and maintaining abstinence. Targeting the withdrawal
symptoms that contribute most to functional impairment during a
quit attempt might be a useful treatment approach (e.g. stress
management techniques to relieve physical tension and possible
pharmacological interventions for alleviating the physical aspects
of withdrawal such as loss of appetite and sleep dysregulation).
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